13F Holdings
中文EN

IMRX Immuneering Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1790340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.4%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.5%
ROA-31.4%
ROIC (approx.)-105.3%
Asset turnover—

Leverage & solvency

Liabilities / assets7.6%
Debt / equity0.00x
Current ratio13.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$0$316,952$2.08M
Cost of revenue——$0$158,122$1.15M
Gross profit——$0$158,830$926,888
R&D expense$42.05M$47.96M$41.62M$36.27M$26.54M
SG&A expense$17.30M$16.08M$16.76M$15.61M$8.27M
Operating income-$59.38M-$64.07M-$58.41M-$51.74M-$33.89M
Pretax income———-$50.51M-$33.84M
Income tax$0———-$307,485
Net income-$56.02M-$61.04M-$53.47M-$50.51M-$33.54M
EBITDA-$59.05M-$63.72M-$58.09M-$51.50M-$33.84M
EPS (basic)-1.27-2.04-1.88-1.91-2.46
EPS (diluted)-1.27-2.04-1.88-1.91-2.46
Weighted avg. shares (diluted)44.01M29.98M28.42M26.39M13.61M
Balance sheet
Cash & equivalents$128.65M$36.14M$59.41M$72.64M$74.89M
Short-term investments—$0$26.26M$32.89M$74.31M
Receivables——$0$12,417$246,040
Current assets$176.25M$39.59M$89.08M$108.75M$152.33M
PP&E, net$938,481$1.12M$1.40M$1.37M$807,223
Goodwill$6.69M$6.69M$6.69M$6.69M$6.70M
Intangibles$321,147$350,413$379,680$408,947$439,000
Total assets$231.99M$52.71M$102.58M$122.37M$166.70M
Current liabilities$10.07M$7.50M$7.85M$8.05M$5.63M
Total liabilities$13.50M$11.33M$12.01M$12.52M$10.72M
Shareholders' equity$218.48M$41.39M$90.58M$109.85M$155.98M
Cash flow statement
Operating cash flow-$45.34M-$55.00M-$48.97M-$44.10M-$30.85M
Capital expenditure$142,226$84,875$342,746$742,483$60,786
Free cash flow-$45.49M-$55.08M-$49.31M-$44.84M-$30.91M
Investing cash flow-$88.74M$26.43M$7.30M$41.83M-$75.62M
Financing cash flow$226.58M$5.30M$28.44M$19,004$144.26M
Depreciation & amortization$324,517$355,807$322,816$247,199$45,467
Stock-based compensation$6.31M$6.50M$5.73M$4.06M$1.80M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.